Cellectis S.A. (NASDAQ:CLLS) Stock Has Average Price Target of $5.46

Cellectis S.A. (NASDAQ:CLLS) has been given an average rating of “Hold” by the seven analysts that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $5.46.

CLLS has been the subject of several recent research reports. Citizens Jmp downgraded Cellectis from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 15th. Robert W. Baird cut their target price on shares of Cellectis from $10.00 to $8.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 15th. Wells Fargo & Company reduced their target price on shares of Cellectis from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Tuesday, September 15th. Barclays downgraded Cellectis from an “overweight” rating to an “underweight” rating and decreased their price objective for the company from $9.00 to $1.30 in a report on Wednesday, September 16th. Finally, Weiss Ratings raised Cellectis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd.

Cellectis Trading Down 7.7%

Shares of Cellectis stock opened at $1.08 on Friday. The firm’s 50 day moving average is $1.89 and its 200 day moving average is $3.07. The firm has a market capitalization of $108.37 million, a PE ratio of -1.66 and a beta of 3.00. Cellectis has a 1 year low of $0.88 and a 1 year high of $5.45. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.04. The company had revenue of $6.90 million during the quarter, compared to the consensus estimate of $11.05 million. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%.

Institutional Investors Weigh In On Cellectis

An institutional investor recently bought a new stake in Cellectis stock. Lido Advisors LLC bought a new position in shares of Cellectis S.A. (NASDAQ:CLLS) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA is a biotechnology company focused on developing gene-edited cell therapies for the treatment of cancer and other serious diseases. Founded in France in 1999, the company pioneered the use of TALEN gene-editing technology to modify immune cells and develop off-the-shelf, or allogeneic, treatments.

The company’s primary programs involve genetically modified T cells, including its UCART platform of allogeneic chimeric antigen receptor T-cell therapies. These products are designed to target specific cancer antigens and are being investigated in clinical studies for hematologic malignancies and other cancers.